Half Year 2024 Galderma Group AG Earnings Call Transcript
Key Points
- Galderma Group AG (GDERF) reported record net sales of $2.2 billion for the first half of 2024, reflecting a strong growth momentum with a 10.8% year-on-year increase at constant currency.
- The company demonstrated broad-based growth across product categories and geographies, with Injectable Aesthetics showing a 13.4% year-on-year growth and Dermatological Skincare achieving an 11.8% increase.
- Galderma Group AG (GDERF) improved its underlying profitability, with a core EBITDA margin of 23.4%, driven by operating leverage and efficiencies from its integrated dermatology platform.
- The company successfully reduced its leverage to 2.6 turns by the end of June, reflecting significant progress in de-leveraging post-IPO.
- Galderma Group AG (GDERF) updated its full-year guidance, expecting net sales growth towards the upper end of the previously communicated range of 7% to 10% at constant currency.
- The US market for fillers experienced some softening, with increased pricing pressure and competition affecting growth dynamics.
- Despite ongoing genericization, Therapeutic Dermatology showed only a modest growth of 2.2% year-on-year, mainly driven by international markets.
- The launch of nemolizumab is anticipated to have a meaningful impact on growth only in 2025, with current preparations and regulatory processes still underway.
- The company faced tighter price competition in Injectable Aesthetics and Dermatological Skincare, impacting gross profit margins.
- Galderma Group AG (GDERF) had to make price concessions in some segments to gain market share, indicating competitive pressures in certain areas.
Welcome to the Galderma H1 '24 financial results call. The press release, along with our financial statements, was published at 7:00 AM Central European Standard Time today and can be consulted on our corporate website at any time. Today's presentation slides as well as a recording of the webcast will be made available on our website after the call. As this is our first financial results call after the Q1 trading update, which covered only net sales, let me take this opportunity to share with you principles of our financial reporting.
A detailed overview can be found in the appendix of this presentation. We provide revenue disclosure by product category and geography, US and international, but we do disclose profitability metrics as a single segment. Our financial disclosure choices reflect our growth-focused, integrated dermatology strategy, which drives value creation by leveraging product and channel synergies across the portfolio as well as efficiencies from a common platform.
Please be advised that today's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
